RevMed’s products include RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter.

RevMed also provides RevColor, RevDisplay and Rev3D software solutions and proprietary tools that are compatible with standard MRIs and standard PACS.

RevMed said that the first study will assess hemorrhagic age and is critical in assessing the proper treatment for head injuries.

Recent data showed that, on average, approximately 1.7 million people sustain a traumatic brain injury annually.

The second study will allow for tissue characterization used in assessing which tissue has been damaged by cancer and which has improved by the cancer treatment protocol, which allows the medical team to alter treatments so that better outcomes are achieved quickly and at less cost.

RevMed president and an early pioneer in the launch of Magnetic Resonance with Johnson & Johnson’s Technicare Tom O’Brien said that with the first application studies they will hopefully realise the dream of the MRI founders.

“Future applications may be possible where we can follow hemorrhage history through clear indications as well as assess effectiveness of cancer treatments more easily through changes in color,” O’Brien said.